Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 19, 2026Journal of Controlled ReleaseOpen Access

Challenging the myths of subcutaneous delivery: An industry expert perspective

View Full Paper
Ask AI
Bookmark
Share

Authors

BBBeate BittnerNBNicole BuistGBGerard Bruin

Discussion

Loading...

Member takes

Overview

Review discusses expert insights on subcutaneous biologic delivery challenges and advancements, highlighting misconceptions and implications.

Key Points

  • This review aims to address misconceptions surrounding subcutaneous delivery of biologics and its adoption.
  • Expert perspectives gathered from a workshop on subcutaneous drug delivery at the 2024 Controlled Release Society Annual Meeting.
  • Collaboration with industry and academic experts in Subcutaneous Drug Development and Delivery Consortium to gather evidence on misconceptions.
  • Increased FDA approvals for subcutaneous treatments indicating changing trends in delivery methods.
  • Challenges remain regarding misconceptions about pain, volume limitations, immunogenicity, and bioavailability.
  • Hope for new advancements to enhance adoption of subcutaneous delivery across disease areas.

Cite This Study

Bittner et al. (2026) studied this question.

synapsesocial.com/papers/6a34dc5265a5b0777af2c985https://doi.org/10.1016/j.jconrel.2026.114902
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Subcutaneous drug delivery of high concentration antibody products – part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentations2026
  2. 2Addressing the needs for large-volume subcutaneous drug delivery: the case for on-body wearable injectors2026
  3. 3Subcutaneous Administration of Antibody–Drug Conjugates: Current Challenges, Emerging Opportunities, and Future Perspectives2026
  4. 4On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives2025 · 8 citations
  5. 5Insights from a Survey of Drug Formulation Experts: Challenges and Preferences in High-Concentration Subcutaneous Biologic Drug Development2025